Pfizer

News

Pfizer sticks $1.5bn on Triana's molecular glue tech

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi

News

Pfizer rounds out haemophilia portfolio with FDA approval

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.

News

Starboard claims Pfizer 'threatened' former leaders

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former executives Ian Read and Frank D'Amelio were bullied into lending their

News

Former Pfizer chief executive and chair Ian Read (l) and former finance chief Frank D’Amelio (r)

Ex-Pfizer leaders side with firm against activist investor

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan.

News

Activist investor Starboard builds $1bn Pfizer stake

The week has started with reports that activist investor Starboard Value has amassed a $1 billion stake in pharma group Pfizer and wants strategic changes to restore growth.

News

Pfizer pulls sickle cell med Oxbryta off market after deaths

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme.

Pfizer sticks $1.5bn on Triana's molecular glue tech

Pfizer rounds out haemophilia portfolio with FDA approval

Starboard claims Pfizer 'threatened' former leaders

Ex-Pfizer leaders side with firm against activist investor

Activist investor Starboard builds $1bn Pfizer stake

Pfizer pulls sickle cell med Oxbryta off market after deaths

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Pfizer

Editor's Picks